203 related articles for article (PubMed ID: 16116042)
1. Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension.
Saha C; Eckert GJ; Ambrosius WT; Chun TY; Wagner MA; Zhao Q; Pratt JH
Hypertension; 2005 Sep; 46(3):481-7. PubMed ID: 16116042
[TBL] [Abstract][Full Text] [Related]
2. Improvement of blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension.
Warnock DG; Bell PD
Hypertension; 2005 Sep; 46(3):469-70. PubMed ID: 16116049
[No Abstract] [Full Text] [Related]
3. Blood pressure responses to small doses of amiloride and spironolactone in normotensive subjects.
Pratt JH; Eckert GJ; Newman S; Ambrosius WT
Hypertension; 2001 Nov; 38(5):1124-9. PubMed ID: 11711509
[TBL] [Abstract][Full Text] [Related]
4. Racial difference in the activity of the amiloride-sensitive epithelial sodium channel.
Pratt JH; Ambrosius WT; Agarwal R; Eckert GJ; Newman S
Hypertension; 2002 Dec; 40(6):903-8. PubMed ID: 12468577
[TBL] [Abstract][Full Text] [Related]
5. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies.
Williams B; MacDonald TM; Morant SV; Webb DJ; Sever P; McInnes GT; Ford I; Cruickshank JK; Caulfield MJ; Padmanabhan S; Mackenzie IS; Salsbury J; Brown MJ;
Lancet Diabetes Endocrinol; 2018 Jun; 6(6):464-475. PubMed ID: 29655877
[TBL] [Abstract][Full Text] [Related]
6. Central role for ENaC in development of hypertension.
Pratt JH
J Am Soc Nephrol; 2005 Nov; 16(11):3154-9. PubMed ID: 16192416
[TBL] [Abstract][Full Text] [Related]
7. The spironolactone, amiloride, losartan, and thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio.
Hood SJ; Taylor KP; Ashby MJ; Brown MJ
Circulation; 2007 Jul; 116(3):268-75. PubMed ID: 17606839
[TBL] [Abstract][Full Text] [Related]
8. Effect of amiloride and spironolactone on renal tubular function and central blood pressure in patients with arterial hypertension during baseline conditions and after furosemide: a double-blinded, randomized, placebo-controlled crossover trial.
Matthesen SK; Larsen T; Vase H; Lauridsen TG; Jensen JM; Pedersen EB
Clin Exp Hypertens; 2013; 35(5):313-24. PubMed ID: 22966789
[TBL] [Abstract][Full Text] [Related]
9. The renal epithelial sodium channel: genetic heterogeneity and implications for the treatment of high blood pressure.
Sagnella GA; Swift PA
Curr Pharm Des; 2006; 12(18):2221-34. PubMed ID: 16787251
[TBL] [Abstract][Full Text] [Related]
10. Amiloride lowers blood pressure and attenuates urine plasminogen activation in patients with treatment-resistant hypertension.
Oxlund CS; Buhl KB; Jacobsen IA; Hansen MR; Gram J; Henriksen JE; Schousboe K; Tarnow L; Jensen BL
J Am Soc Hypertens; 2014 Dec; 8(12):872-81. PubMed ID: 25492830
[TBL] [Abstract][Full Text] [Related]
11. Blood pressure lowering efficacy of potassium-sparing diuretics (that block the epithelial sodium channel) for primary hypertension.
Heran BS; Chen JM; Wang JJ; Wright JM
Cochrane Database Syst Rev; 2012 Nov; 11():CD008167. PubMed ID: 23152254
[TBL] [Abstract][Full Text] [Related]
12. Blood pressure lowering efficacy of potassium-sparing diuretics (that block the epithelial sodium channel) for primary hypertension.
Heran BS; Chen JM; Wang JJ; Wright JM
Cochrane Database Syst Rev; 2010 Jan; (1):CD008167. PubMed ID: 20091662
[TBL] [Abstract][Full Text] [Related]
13. Amiloride, a specific drug for hypertension in black people with T594M variant?
Baker EH; Duggal A; Dong Y; Ireson NJ; Wood M; Markandu ND; MacGregor GA
Hypertension; 2002 Jul; 40(1):13-7. PubMed ID: 12105131
[TBL] [Abstract][Full Text] [Related]
14. Genetic variation in CYP4A11 and blood pressure response to mineralocorticoid receptor antagonism or ENaC inhibition: an exploratory pilot study in African Americans.
Laffer CL; Elijovich F; Eckert GJ; Tu W; Pratt JH; Brown NJ
J Am Soc Hypertens; 2014 Jul; 8(7):475-80. PubMed ID: 25064769
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients.
Flack JM; Oparil S; Pratt JH; Roniker B; Garthwaite S; Kleiman JH; Yang Y; Krause SL; Workman D; Saunders E
J Am Coll Cardiol; 2003 Apr; 41(7):1148-55. PubMed ID: 12679215
[TBL] [Abstract][Full Text] [Related]
16. Epithelial sodium channel blockade and new β-ENaC polymorphisms among normotensive and hypertensive adult Nigerians.
Elias SO; Sofola OA; Jaja SI
Clin Exp Hypertens; 2019; 41(2):144-151. PubMed ID: 29580127
[TBL] [Abstract][Full Text] [Related]
17. Epithelial sodium channel allele T594M is not associated with blood pressure or blood pressure response to amiloride.
Hollier JM; Martin DF; Bell DM; Li JL; Chirachanchai MG; Menon DV; Leonard D; Wu X; Cooper RS; McKenzie C; Victor RG; Auchus RJ
Hypertension; 2006 Mar; 47(3):428-33. PubMed ID: 16432044
[TBL] [Abstract][Full Text] [Related]
18. The importance of the epithelial sodium channel in determining salt sensitivity in people of African origin.
Jones E; Rayner B
Pediatr Nephrol; 2021 Feb; 36(2):237-243. PubMed ID: 31897716
[TBL] [Abstract][Full Text] [Related]
19. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study.
Weber MA; Mansfield TA; Cain VA; Iqbal N; Parikh S; Ptaszynska A
Lancet Diabetes Endocrinol; 2016 Mar; 4(3):211-220. PubMed ID: 26620248
[TBL] [Abstract][Full Text] [Related]
20. The association of the R563Q genotype of the ENaC with phenotypic variation in Southern Africa.
Jones ES; Owen EP; Rayner BL
Am J Hypertens; 2012 Dec; 25(12):1286-91. PubMed ID: 22895453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
